Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: July 20, 2011
Event: Announcement of results of operations for the second quarter of 2011.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that these results were announced and refers to a press release (Exhibit 99.1) for the detailed data.
The filing notes the use of non-GAAP financial measures, including:
- Net earnings excluding specified items.
- Diluted earnings per common share excluding specified items.
Material Changes and Adjustments
The filing does not list specific material changes in financial performance versus the prior period. However, it details the types of unusual or unpredictable factors that management adjusts for in their non-GAAP reporting, including:
- Acquisition-related costs.
- Asset impairments.
- Currency devaluations.
- Legislative reforms.
- Litigation reserves.
- Acquired in-process research and development.
- Tax audit settlements.
- Restructuring and cost reduction initiatives.
- Effects of changes in the calendar year-end for international operations.
Guidance, Outlook, and Management Commentary
Management commentary indicates that non-GAAP measures are used internally to monitor business performance and are presented to help investors evaluate ongoing operations. Management cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures. The filing does not contain specific forward-looking guidance or risk factors beyond the general caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 20, 2011) for specific Q2 2011 revenue and earnings figures.
- Compare GAAP results against the non-GAAP adjustments listed to understand the impact of one-time items.
- Verify the specific impact of currency devaluations and legislative reforms on the quarter's performance.
- Confirm the details of any restructuring or cost reduction initiatives mentioned in the full press release.